Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report
Open Access
- 21 May 2021
- journal article
- case report
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 1938-1945
Abstract
Gene alteration in anaplastic lymphoma kinase (ALK) is rare, and the efficacy of ALK inhibitors in the treatment of carcinoma of unknown primary (CUP) with ALK alteration remains unclear. The patient was a 56-year-old woman who presented with cervical lymph node swelling. Computed tomography revealed paraaortic, perigastric, and cervical lymph node swelling; ascites; a liver lesion; and a left adrenal mass. A cervical lymph node biopsy was performed, and pathological diagnosis of an undifferentiated malignant tumor was conducted. Finally, the patient was diagnosed with CUP and treated with chemotherapy. To evaluate actionable mutations, we performed a multigene analysis, using a next-generation sequencer (FoundationOne® CDx). It revealed that the tumor harbored an echinoderm microtubule-associated protein-like 4 (EML4) and ALK fusion gene. Additionally, immunohistochemistry confirmed ALK protein expression. Alectinib, a potent ALK inhibitor, was recommended for the patient at a molecular oncology conference at our institution. Accordingly, alectinib (600 mg/day) was administered, and the multiple lesions and symptoms rapidly diminished without apparent toxicity. The administration of alectinib continued for a period of 10 months without disease progression. Thus, ALK-tyrosine kinase inhibitors should be considered in patients with CUP harboring the EML4-ALK fusion gene.Keywords
This publication has 16 references indexed in Scilit:
- Clinical and molecular characterization of patients with cancer of unknown primary in the modern eraAnnals of Oncology, 2017
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Cancer Discovery, 2017
- A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary siteCancer Chemotherapy and Pharmacology, 2015
- Metastatic Carcinoma of Unknown PrimaryAdvances in Anatomic Pathology, 2015
- Carcinomas of an unknown primary origin—diagnosis and treatmentNature Reviews Clinical Oncology, 2011
- Exon Array Profiling DetectsEML4-ALKFusion in Breast, Colorectal, and Non–Small Cell Lung CancersMolecular Cancer Research, 2009
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onsetLaboratory Investigation, 2009
- Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic FactorsSeminars in Oncology, 2009
- Treatment of Patients with Cancer of an Unknown Primary SiteNew England Journal of Medicine, 1993